Crédit Industriel et Commercial’s Esperion Therapeutics ESPR Stock Holding History

Crédit Industriel et Commercial’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.3M	Buy	+1,044,420	New	+$2.92M	0.21%	100

Other funds holding ESPR

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Transmarket Holdings Chicago, Illinois $136M AUM

Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Eleva Capital Paris, France $343M AUM

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Crédit Industriel et Commercial's ESPR Position: Q2 2026 in Review

Crédit Industriel et Commercial opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 1,044,420 shares worth $3.3M. The stake represents 0.21% of the portfolio and ranks #100 among its holdings.

27 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Crédit Industriel et Commercial held 1,044,420 shares of Esperion Therapeutics worth $3.3M as of Q2 2026.
Esperion Therapeutics was a new Crédit Industriel et Commercial position in Q2 2026.
Esperion Therapeutics made up 0.21% of Crédit Industriel et Commercial's portfolio in Q2 2026, its #100 holding.
27 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Crédit Industriel et Commercial's 13F filing for Q2 2026, filed 24 Jul 2026.